The primary objective of this project is to support the advanced development of candidate products for use in post-event settings following the intentional release of or in response to naturally occurring outbreaks of infectious diseases caused by NIAID Category A, B, and C Priority Pathogens. This contract may support formulation and manufacture of the individual vaccine components, as well as stability testing, nonclinical immunogenicity and efficacy testing in nonhuman primates, IND enabling GLP repeated dose toxicology, submission of an IND and eventual clinical evaluation.